BR0308145A - Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto - Google Patents
Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um compostoInfo
- Publication number
- BR0308145A BR0308145A BR0308145-1A BR0308145A BR0308145A BR 0308145 A BR0308145 A BR 0308145A BR 0308145 A BR0308145 A BR 0308145A BR 0308145 A BR0308145 A BR 0308145A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- hydroxy
- halo
- alkyl
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE UM COMPOSTO, E, PROCESSO PARA A PREPARAçãO DE UM COMPOSTO". Amidas heterocíclicas da fórmula (1): em que: Z é CH ou nitrogênio; R^ 4^ e R^ 5^ juntos são ou -S-C(R^ 6^)=C(R^ 7^)- ou -C(R^ 7^)=C(R^ 6^)-S-; R^ 6^ e R^ 7^ são selecionados a partir, por exemplo, de hidrogênio, halo, alquila C~ 1-4~ e alcanoíla C~ 1-4~; A é fenileno ou heteroarileno; n é 0, 1 ou 2; R^ 1^ é selecionado, por exemplo, a partir de halo, nitro, ciano, hidróxi, carbóxi; r é 1 ou 2; Y é -NR^ 2^R^ 3^ ou - OR^ 3^; R^ 2^ e R^ 3^ são selecionados a partir de, por exemplo, hidrogênio, hidróxi, arila, heterociclila e alquila C~ 1-4~ (opcionalmente substituído por 1 ou 2 grupos R^ 8^); R^ 4^ é selecionado, por exemplo, a partir de hidrogênio, halo, nitro, ciano, hidróxi, alquila C~ 1-4~ e alcanoíla; R^ 8^ é selecionado, por exemplo, a partir de hidróxi, -COCOOR^ 9^,- C(O)N(R^ 9^)(R^ 10^), - NHC(O)R^ 9^, (R^ 9^) (R^ 10^)N- e -COOR^ 9^; R^ 9^ e R^ 10^ são selecionados, por exemplo, a partir de hidrogênio, hidróxi, alquila C~ 1-4~ (opcionalmente substituido por 1 ou 2 R^ 13^); R^ 13^ é selecionado a partir de hidróxi, halo, trifluorometila e alcóxi C~ 1-4~; ou um sal farmaceuticamente aceitável ou pró-droga dos mesmos; possuem atividade inibitória de glicogênio fosforilase e portanto possuem valor no tratamento de estados de doença associados com atividade de glicogênio fosforilase aumentada. Processos para a manufatura dos referidos derivados de amida heterocíclica e composições farmacêuticas contendo os mesmos são descritos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0205170.4A GB0205170D0 (en) | 2002-03-06 | 2002-03-06 | Chemical compounds |
| PCT/GB2003/000875 WO2003074531A1 (en) | 2002-03-06 | 2003-03-04 | Heterocyclic amide derivatives having glycogen phosphorylase inhibitory activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0308145A true BR0308145A (pt) | 2004-12-07 |
Family
ID=9932334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0308145-1A BR0308145A (pt) | 2002-03-06 | 2003-03-04 | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US7122567B2 (pt) |
| EP (1) | EP1483271B1 (pt) |
| JP (1) | JP2005524669A (pt) |
| KR (1) | KR20040091101A (pt) |
| CN (1) | CN1307183C (pt) |
| AR (1) | AR038886A1 (pt) |
| AT (1) | ATE346072T1 (pt) |
| AU (1) | AU2003209445A1 (pt) |
| BR (1) | BR0308145A (pt) |
| CA (1) | CA2477125A1 (pt) |
| DE (1) | DE60309849T2 (pt) |
| DK (1) | DK1483271T3 (pt) |
| ES (1) | ES2276092T3 (pt) |
| GB (1) | GB0205170D0 (pt) |
| IL (1) | IL163802A0 (pt) |
| IS (1) | IS7433A (pt) |
| MX (1) | MXPA04008611A (pt) |
| NO (1) | NO20044033L (pt) |
| NZ (1) | NZ534684A (pt) |
| PL (1) | PL372772A1 (pt) |
| PT (1) | PT1483271E (pt) |
| RU (1) | RU2004125145A (pt) |
| TW (1) | TW200306176A (pt) |
| WO (1) | WO2003074531A1 (pt) |
| ZA (1) | ZA200406685B (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0222912D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| GB0222909D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| ES2393996T3 (es) | 2002-12-25 | 2013-01-04 | Daiichi Sankyo Company, Limited | Derivados de diaminociclohexano antitrombóticos |
| JP4630267B2 (ja) * | 2002-12-25 | 2011-02-09 | 第一三共株式会社 | ジアミン誘導体 |
| GB0318463D0 (en) * | 2003-08-07 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| GB0319759D0 (en) * | 2003-08-22 | 2003-09-24 | Astrazeneca Ab | Chemical compounds |
| AU2004312530A1 (en) | 2003-12-29 | 2005-07-21 | Sepracor Inc. | Pyrrole and pyrazole DAAO inhibitors |
| WO2006055463A2 (en) * | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| US7223786B2 (en) | 2004-11-15 | 2007-05-29 | Bristol-Myers Squibb Company | 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors |
| US7226942B2 (en) | 2004-11-15 | 2007-06-05 | Bristol-Myers Squibb Company | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| WO2006053274A2 (en) * | 2004-11-15 | 2006-05-18 | Bristol-Myers Squibb Company | 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| TWI281231B (en) * | 2004-12-20 | 2007-05-11 | Hynix Semiconductor Inc | Method for forming storage node of capacitor in semiconductor device |
| NZ569608A (en) | 2006-01-06 | 2011-09-30 | Sepracor Inc | Tetralone-based monoamine reuptake inhibitors |
| BRPI0706365A2 (pt) | 2006-01-06 | 2011-03-22 | Sepracor Inc | Cicloalquilaminas como inibidores da recaptação de monoamina |
| DK2816024T3 (en) | 2006-03-31 | 2017-10-30 | Sunovion Pharmaceuticals Inc | CHIRALE AMINER |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| US7884124B2 (en) | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| US7902252B2 (en) | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
| AU2008259841B2 (en) | 2007-05-31 | 2015-02-05 | Sunovion Pharmaceuticals Inc. | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE200740C (pt) | ||||
| US3706810A (en) * | 1970-09-15 | 1972-12-19 | American Cyanamid Co | N-morpholinoalkyl-thieno(3,2-b)pyrrole-5-carboxamides |
| US4668769A (en) | 1985-08-02 | 1987-05-26 | Hoover Dennis J | Oxa- and azahomocyclostatine polypeptides |
| US4599198A (en) | 1985-08-02 | 1986-07-08 | Pfizer Inc. | Intermediates in polypeptide synthesis |
| US4720503A (en) | 1985-08-02 | 1988-01-19 | Merck & Co., Inc. | N-substituted fused-heterocyclic carboxamide derivatives as dual cyclooxygenase and lipoxygenase inhibitors |
| FR2601368B1 (fr) | 1986-07-08 | 1989-04-07 | Synthelabo | Derives de nitrofuranne, leur preparation et leur application en therapeutique. |
| DE3629545A1 (de) | 1986-08-30 | 1988-03-10 | Bayer Ag | Dihydropyridinverbindungen, verfahren zu ihrer herstellung und ihre verwendung |
| US4751231A (en) | 1987-09-16 | 1988-06-14 | Merck & Co., Inc. | Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents |
| JPH04179949A (ja) | 1990-11-15 | 1992-06-26 | Fuji Photo Film Co Ltd | 新規な色素形成カプラーおよび該カプラーを用いたハロゲン化銀カラー写真感光材料 |
| EP0644892A1 (en) | 1992-06-12 | 1995-03-29 | Pfizer Inc. | Inhibitors of angiotensin i chymase(s) including human heart chymase |
| ES2081747B1 (es) | 1993-09-07 | 1997-01-16 | Esteve Labor Dr | Amidas derivadas de tienopirroles, su preparacion y su aplicacion como medicamentos. |
| US5863903A (en) | 1994-03-09 | 1999-01-26 | Novo Nordisk A/S | Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes |
| ATE243196T1 (de) | 1994-03-09 | 2003-07-15 | Novo Nordisk As | Piperidine und pyrrolidine |
| FR2723739B1 (fr) | 1994-08-19 | 1997-02-14 | Sanofi Sa | Derives de glycinamide, procedes pour leur preparation et medicaments les contenant. |
| DE4445968A1 (de) | 1994-12-22 | 1996-06-27 | Bayer Ag | Verwendung von Sulfonylguanazinen |
| DE69523182T2 (de) | 1995-06-06 | 2002-02-07 | Pfizer | Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren |
| EP1134213B1 (en) | 1995-06-06 | 2005-11-02 | Pfizer Inc. | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides |
| FI974437A7 (fi) | 1995-06-06 | 1997-12-05 | Pfizer | Substituoituja N-(indoli-2-karbonyyli)amideja ja johdannaisia glykogee nifosforylaasi-inhibiittoreina |
| CZ120398A3 (cs) | 1995-09-08 | 1998-12-16 | Novo Nordisk A/S | Použití 2-alkylpyrrolidinových derivátů pro přípravu léčiva pro léčbu diabetu, 2-alkylpyrrolidiné deriváty |
| AU2090897A (en) | 1996-02-29 | 1997-09-16 | Mikael Bols | Hydroxyhexahydropyridazines |
| US6069162A (en) | 1996-05-27 | 2000-05-30 | Fujisawa Pharmaceutical Co., Ltd. | Indolyl and benzofuranyl carboxamides as inhibitors of nitric oxide production |
| US5952322A (en) * | 1996-12-05 | 1999-09-14 | Pfizer Inc. | Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors |
| EP0946587A2 (en) | 1996-12-16 | 1999-10-06 | Fujisawa Pharmaceutical Co., Ltd. | New amide compounds |
| WO1998040353A1 (en) | 1997-03-07 | 1998-09-17 | Novo Nordisk A/S | Novel heterocyclic compounds |
| WO1998050359A1 (en) | 1997-05-06 | 1998-11-12 | Novo Nordisk A/S | Novel heterocyclic compounds |
| UA57811C2 (uk) | 1997-11-21 | 2003-07-15 | Пфайзер Продактс Інк. | Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності |
| MY153569A (en) | 1998-01-20 | 2015-02-27 | Mitsubishi Tanabe Pharma Corp | Inhibitors of ?4 mediated cell adhesion |
| US5998463A (en) * | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
| EP0978279A1 (en) | 1998-08-07 | 2000-02-09 | Pfizer Products Inc. | Inhibitors of human glycogen phosphorylase |
| WO2000042213A1 (en) | 1999-01-13 | 2000-07-20 | The Research Foundation Of State University Of New York | A novel method for designing protein kinase inhibitors |
| JP2002536410A (ja) | 1999-02-12 | 2002-10-29 | ノボ ノルディスク アクティーゼルスカブ | 肥満の治療又は予防もしくは食欲の調節を目的とした薬学的組成物の製造におけるピロリジン誘導体の使用 |
| US6043091A (en) | 1999-07-19 | 2000-03-28 | Isis Pharmaceuticals Inc. | Antisense modulation of liver glycogen phosphorylase expression |
| JP3795305B2 (ja) | 1999-07-19 | 2006-07-12 | 田辺製薬株式会社 | 医薬組成物 |
| AU7404700A (en) | 1999-09-29 | 2001-04-30 | Novo Nordisk A/S | Novel aromatic compounds |
| ATE257480T1 (de) * | 1999-09-30 | 2004-01-15 | Pfizer Prod Inc | Bicyclische pyrrolylamide als glycogenphosphorylase-inhibitoren |
| SE9903998D0 (sv) | 1999-11-03 | 1999-11-03 | Astra Ab | New compounds |
| BR0015315A (pt) | 1999-11-05 | 2002-06-25 | Sod Conseils Rech Applic | Compostos, medicamentos, composições farmacêuticas, utilização de compostos e produtos industriais |
| EP1743655B1 (en) | 2000-01-21 | 2014-06-25 | Novartis AG | Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents |
| CO5271699A1 (es) | 2000-01-24 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa |
| US6555569B2 (en) | 2000-03-07 | 2003-04-29 | Pfizer Inc. | Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| US20010053791A1 (en) | 2000-03-16 | 2001-12-20 | Babcock Walter C. | Glycogen phosphorylase inhibitor |
| PE20011184A1 (es) | 2000-03-16 | 2001-11-15 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa |
| EP1136071A3 (en) | 2000-03-22 | 2003-03-26 | Pfizer Products Inc. | Use of glycogen phosphorylase inhibitors |
| ATE266409T1 (de) | 2000-04-13 | 2004-05-15 | Pfizer Prod Inc | Synergistische wirkung von glyburide und milrinone |
| NZ523034A (en) | 2000-06-09 | 2004-07-30 | Aventis Pharma Gmbh | Acylphenyl urea derivatives, methods for the production thereof and use thereof as a medicament |
| US20020028826A1 (en) | 2000-06-15 | 2002-03-07 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| US20020013334A1 (en) | 2000-06-15 | 2002-01-31 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| IL144507A0 (en) | 2000-07-31 | 2002-05-23 | Pfizer Prod Inc | Use of glycogen phosphorylase inhibitors to inhibit tumor growth |
| GB0021831D0 (en) | 2000-09-06 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| WO2002026714A1 (en) | 2000-09-27 | 2002-04-04 | Takeda Chemical Industries, Ltd. | Spiro compounds |
| HU227197B1 (en) | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| US6933317B2 (en) | 2000-11-01 | 2005-08-23 | Shionogi & Co. Ltd. | PGD2 receptor antagonistic pharmaceutical compositions |
| WO2002080844A2 (en) | 2001-04-04 | 2002-10-17 | Genzyme Corporation | Novel bgp compounds for therapy and diagnosis and methods for using same |
| PE20021091A1 (es) | 2001-05-25 | 2003-02-04 | Aventis Pharma Gmbh | Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion |
| AU2002308706A1 (en) | 2001-06-01 | 2002-12-16 | Eli Lilly And Company | Glp-1 formulations with protracted time action |
| US20050054696A1 (en) | 2001-10-29 | 2005-03-10 | Takeshi Nakamura | Indole compounds and medicinal use thereof |
| CA2468159A1 (en) | 2001-11-27 | 2003-06-05 | Merck & Co., Inc. | 4-aminoquinoline compounds |
| MXPA03000966A (es) | 2002-02-28 | 2003-09-04 | Pfizer Prod Inc | Agentes antidiabeticos. |
| GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
| WO2003091213A1 (en) | 2002-04-25 | 2003-11-06 | Yamanouchi Pharmaceutical Co., Ltd. | Novel amide derivatives or salts thereof |
| US7057046B2 (en) | 2002-05-20 | 2006-06-06 | Bristol-Myers Squibb Company | Lactam glycogen phosphorylase inhibitors and method of use |
| GB0222909D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| GB0222912D0 (en) | 2002-10-03 | 2002-11-13 | Astrazeneca Ab | Novel process and intermediates |
| CA2503727A1 (en) | 2002-11-07 | 2004-05-21 | Pfizer Products Inc. | Anti-diabetic agents |
| US7098235B2 (en) | 2002-11-14 | 2006-08-29 | Bristol-Myers Squibb Co. | Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds |
| JP2004196702A (ja) | 2002-12-18 | 2004-07-15 | Yamanouchi Pharmaceut Co Ltd | 新規なアミド誘導体又はその塩 |
| US7501440B2 (en) | 2003-03-07 | 2009-03-10 | Sanofi-Aventis Deutschland Gmbh | Substituted benzoylureidopyridylpiperidine-and-pyrrolidinecarboxylic acid derivatives, processes for preparing them and their use |
| EP1620427A1 (en) | 2003-04-17 | 2006-02-01 | Pfizer Products Inc. | Carboxamide derivatives as anti-diabetic agents |
| WO2004096768A1 (en) | 2003-04-30 | 2004-11-11 | Pfizer Products Inc. | Anti-diabetic agents |
| WO2004113345A1 (ja) | 2003-06-20 | 2004-12-29 | Japan Tobacco Inc. | 縮合ピロール化合物及びその医薬用途 |
| GB0318464D0 (en) | 2003-08-07 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| GB0318463D0 (en) | 2003-08-07 | 2003-09-10 | Astrazeneca Ab | Chemical compounds |
| GB0319690D0 (en) | 2003-08-22 | 2003-09-24 | Astrazeneca Ab | Chemical compounds |
| GB0319759D0 (en) | 2003-08-22 | 2003-09-24 | Astrazeneca Ab | Chemical compounds |
| WO2005020986A1 (en) | 2003-08-29 | 2005-03-10 | Astrazeneca Ab | Heterocyclic amide derivatives which posses glycogen phosphorylase inhibitory activity |
| WO2005020985A1 (en) | 2003-08-29 | 2005-03-10 | Astrazeneca Ab | Indolamide derivatives which possess glycogen phosphorylase inhibitory activity |
| GB0320422D0 (en) | 2003-08-30 | 2003-10-01 | Astrazeneca Ab | Chemical compounds |
-
2002
- 2002-03-06 GB GBGB0205170.4A patent/GB0205170D0/en not_active Ceased
-
2003
- 2003-03-04 DK DK03743418T patent/DK1483271T3/da active
- 2003-03-04 US US10/506,746 patent/US7122567B2/en not_active Expired - Fee Related
- 2003-03-04 AT AT03743418T patent/ATE346072T1/de not_active IP Right Cessation
- 2003-03-04 EP EP03743418A patent/EP1483271B1/en not_active Expired - Lifetime
- 2003-03-04 CA CA002477125A patent/CA2477125A1/en not_active Abandoned
- 2003-03-04 KR KR10-2004-7013865A patent/KR20040091101A/ko not_active Ceased
- 2003-03-04 PL PL03372772A patent/PL372772A1/xx not_active Application Discontinuation
- 2003-03-04 BR BR0308145-1A patent/BR0308145A/pt not_active IP Right Cessation
- 2003-03-04 WO PCT/GB2003/000875 patent/WO2003074531A1/en not_active Ceased
- 2003-03-04 ES ES03743418T patent/ES2276092T3/es not_active Expired - Lifetime
- 2003-03-04 AU AU2003209445A patent/AU2003209445A1/en not_active Abandoned
- 2003-03-04 NZ NZ534684A patent/NZ534684A/en unknown
- 2003-03-04 CN CNB038051249A patent/CN1307183C/zh not_active Expired - Fee Related
- 2003-03-04 MX MXPA04008611A patent/MXPA04008611A/es active IP Right Grant
- 2003-03-04 PT PT03743418T patent/PT1483271E/pt unknown
- 2003-03-04 JP JP2003572999A patent/JP2005524669A/ja not_active Withdrawn
- 2003-03-04 DE DE60309849T patent/DE60309849T2/de not_active Expired - Fee Related
- 2003-03-04 RU RU2004125145/04A patent/RU2004125145A/ru not_active Application Discontinuation
- 2003-03-04 IL IL16380203A patent/IL163802A0/xx unknown
- 2003-03-05 TW TW092104655A patent/TW200306176A/zh unknown
- 2003-03-06 AR ARP030100766A patent/AR038886A1/es unknown
-
2004
- 2004-08-23 ZA ZA200406685A patent/ZA200406685B/en unknown
- 2004-09-01 IS IS7433A patent/IS7433A/is unknown
- 2004-09-24 NO NO20044033A patent/NO20044033L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1483271A1 (en) | 2004-12-08 |
| NO20044033L (no) | 2004-11-25 |
| RU2004125145A (ru) | 2005-06-10 |
| KR20040091101A (ko) | 2004-10-27 |
| PL372772A1 (en) | 2005-08-08 |
| CN1307183C (zh) | 2007-03-28 |
| WO2003074531A1 (en) | 2003-09-12 |
| DE60309849D1 (de) | 2007-01-04 |
| DE60309849T2 (de) | 2007-06-14 |
| JP2005524669A (ja) | 2005-08-18 |
| ATE346072T1 (de) | 2006-12-15 |
| TW200306176A (en) | 2003-11-16 |
| CA2477125A1 (en) | 2003-09-12 |
| IS7433A (is) | 2004-09-01 |
| ZA200406685B (en) | 2005-10-31 |
| US20050131052A1 (en) | 2005-06-16 |
| PT1483271E (pt) | 2007-02-28 |
| AU2003209445A1 (en) | 2003-09-16 |
| NZ534684A (en) | 2006-02-24 |
| MXPA04008611A (es) | 2004-12-06 |
| HK1070365A1 (en) | 2005-06-17 |
| EP1483271B1 (en) | 2006-11-22 |
| GB0205170D0 (en) | 2002-04-17 |
| US7122567B2 (en) | 2006-10-17 |
| IL163802A0 (en) | 2005-12-18 |
| AR038886A1 (es) | 2005-02-02 |
| CN1639167A (zh) | 2005-07-13 |
| DK1483271T3 (da) | 2007-02-19 |
| ES2276092T3 (es) | 2007-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0308145A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
| BR0308146A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
| BR0308144A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto | |
| BRPI0413232B8 (pt) | composto tendo atividade inibitória contra transportador dependente de sódio, composição farmacêutica compreendendo o composto, uso do composto na preparação de um medicamento e processo para a preparação do composto | |
| NO986055D0 (no) | Nye heterocykliske forbindelser, deres fremstilling, farmas÷ytiske preparat | |
| ATE126216T1 (de) | Pyrazolderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellung. | |
| BRPI0614168A2 (pt) | Composto ou um sal, hidrato, solvato, isoforma, tautômero, isômero óptico farmaceuticamente aceitável ou uma combinação dos mesmos, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psquiátricos, uso de um composto, e, processo para a preparação de um composto | |
| BR0214989A (pt) | Composto, formulação farmacêutica, uso de um composto, método de tratamento de doenças, e, processo para a preparação de um composto | |
| BRPI0416004A (pt) | composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método para o tratamento de doenças mediadas por glk, uso de um composto ou um sal, solvato ou pró-droga do mesmo, métodos para o tratamento combinado de obesidade e diabetes e para o tratamento de obesidade, e, processo para a preparação de um composto ou um sal, pró-droga ou solvato do mesmo | |
| BRPI0409227B8 (pt) | "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)" | |
| BRPI0414514A (pt) | uso de um composto, composto, e, composições farmacêuticas | |
| BRPI0215312B8 (pt) | composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto | |
| DE69615674D1 (de) | Cyclobutan-derivate als inhibitoren der squalen-synthase und der protein farnesyltransferase | |
| ATE212991T1 (de) | Thiazolidinedione- und oxazolidinedione-derivate mit antidiabetischen, hypolipidämischen und anti hypertensiven eigenschaften | |
| MXPA02011974A (es) | Derivados de quinazolina sustituidos y su uso como inhibidores. | |
| BRPI0413233A (pt) | novos compostos | |
| MY140528A (en) | Spiroketal derivatives and their use as therapeutic agents for diabetes | |
| BRPI0517423A (pt) | composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto | |
| BR0008770A (pt) | Derivado de pirimidina, processo para a preparação de um derivado de pirimidina, processo para a produção de um efeito anti-câncer em um animal de sangue quente, uso de um derivado de pirimidina, e, composição farmacêutica | |
| BR9911013A (pt) | Derivados de pirazol como inibidores da p-38 map quinase | |
| BRPI0309534B8 (pt) | derivados de triazol como antagonistas do receptor de taquicinina, seu uso, e composição farmacêutica | |
| BR9910467A (pt) | Composto derivado de amida, processo para a preparação do mesmo, composição farmacêutica, e, uso de um composto derivado de amida | |
| ES2161418T3 (es) | Compuestos de piridilfurano y de piridiltiofeno y uso farmaceutico de los mismos. | |
| CA2523261A1 (en) | Fused pyrimidine derivatives with crf activity | |
| EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A E 8A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011. |